RXRX — RECURSION PHARMACEUTICALS, INC.

Nasdaq · Health Care · Biotechnology · CIK 1601830 ·
Last close
$3.00
Market Cap
$1.57B
52W High
$4.09
52W Low
$2.77
ADV30
22,550,633
Next earnings
2026-08-05
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 6,301,000 -6,189,000 -128,505,000 -117,504,000 1,339,522,000 654,473,000 314,753,000
Dec 2025 35,351,000 21,076,000 -108,334,000 -108,122,000 1,474,130,000 743,294,000 343,265,000
Sep 2025 4,983,000 -9,704,000 -172,202,000 -162,253,000 1,399,526,000 659,836,000 352,578,000
Jun 2025 19,103,000 -1,058,000 -176,227,000 -171,897,000 1,302,355,000 525,110,000 383,209,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-320,952,000
Investing CF
$-9,939,000
Financing CF
$477,535,000
CapEx
$-7,133,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.20
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,193,506,000
Inventory
Receivables
$13,585,000
ST Investments
EBIT TTM
$-562,704,000
Pretax Income TTM
$-564,356,000
Interest Exp TTM
$1,652,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$66,408,000
EBITDA
$-501,225,984
Free Cash Flow
$-177,795,632
Enterprise Value
$1,007,617,600
Total Cash
$654,473,024
Total Debt
$72,375,000
Shares Out
524,677,865
Trailing EPS
$-1.16
Book Value
$1.93
ROE
-57.2%
ROA
-27.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 74,256,000 -648,132,000 -644,759,000 1,474,130,000 343,265,000 -371,808,000
Dec 2024 58,488,000 -479,004,000 -463,661,000 1,448,598,000 413,816,000 -359,174,000
Dec 2023 43,876,000 -350,060,000 -328,066,000 653,699,000 190,263,000 -287,780,000
Dec 2022 39,681,000 -245,727,000 -239,476,000 701,288,000 215,482,000 -83,524,000

TTM Snapshot

Revenues TTM
$52,309,000
NetIncome TTM
$-296,732,000
OpCashFlow TTM
$0
Assets (Latest)
$1,448,598,000
Forward EPS
$-0.94

Max Pain — expiry 2026-08-07

max pain strike: $3.00 · spot: $3.00 · call oi: 4,393 · put oi: 2,829
Expected Move to 2026-08-07: ±$0.29 (9.50%) — implied range $2.71$3.29 · ATM straddle on $3.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MAZE Maze Therapeutics, Inc. $1.49B $26.92
SLBT SL Science Holding Ltd $1.48B $2.64
TSHA Taysha Gene Therapies, Inc. $1.68B $5.86
VIR Vir Biotechnology, Inc. $1.46B $8.66
IMCR Immunocore Holdings plc $1.72B $33.81

News headlines (Yahoo Finance, 1h cache)

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
2026-07-31 20:30 · Yahoo
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
2026-07-29 21:45 · Yahoo
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
2026-07-29 12:30 · Yahoo
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
2026-07-27 21:50 · Yahoo
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
2026-07-24 13:10 · Yahoo
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
2026-07-20 21:50 · Yahoo
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
2026-07-14 21:50 · Yahoo
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?
2026-07-14 09:17 · Yahoo
2 Beaten-Down Stocks That Still Aren't Worth Buying
2026-07-11 20:50 · Yahoo
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?
2026-07-09 17:29 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.